Drug Profile

Nav1.8 antisense oligonucleotide - Quiver Bioscience

Alternative Names: Nav1.8 ASO - Quiver Bioscience

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Q-State Biosciences
Developer Quiver Bioscience
Class Antisense oligonucleotides; Non-opioid analgesics
Mechanism of Action NAV1.8 voltage gated sodium channel expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

23 Jul 2021 Nav1.8 antisense oligonucleotide - Q-State Biosciences is available for licensing as of 23 Jul 2021. (https://www.qstatebio.com/partnerships)
23 Jul 2021 Early research in Pain in USA (Parenteral) (Q-State Biosciences pipeline, July 2021)
06 Jan 2020 Q-State Biosciences receives SBIR grant from National Institutes of Health for development of ASO therapeutics for cancer pain

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com